accretion nutraveda reported a significant acceleration in financial performance for FY26, with revenue from operations jumping 110% year-on-year to ₹3,360.31 lacs. The Ahmedabad-based Contract Development and Manufacturing Organization (CDMO) saw its Net Profit After Tax (PAT) rise 103% to ₹506.83 lacs, reflecting strong execution in the Ayurvedic and nutraceutical segments. This growth trajectory was bolstered by the company’s transition to a publicly listed entity on the BSE SME platform in February 2026.

The filing, submitted under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company's fifth Annual General Meeting scheduled for August 27, 2026. Shareholders will vote on special resolutions regarding the appointment of two independent directors, Chand Rameshbhai Kanabar and Grishma A Shewale, and revisions to the remuneration of six key managerial personnel. The Board also noted that no dividend was recommended for the year, as proceeds are being reinvested into capacity expansion and automation.

Financial Performance

The company’s top-line growth was driven by increased volumes across multiple dosage forms, particularly external preparations and capsules. EBITDA expanded by 88% to ₹700.59 lacs, although the EBITDA margin contracted slightly to 20.85% from 22.79% in the prior year, indicating higher investment in raw materials or production scaling relative to revenue gains.

Earnings Per Share (EPS) stood at ₹9.35 for FY26, compared to ₹6.88 in FY25. The prior year’s EPS has been restated to reflect the bonus issue of 47.88 lakh shares executed in September 2025.

Capital Raises and Liquidity

A pivotal event during FY26 was the successful Initial Public Offering (IPO), which raised ₹24.77 crore through the allotment of 19.20 lakh equity shares at ₹129 per share. The IPO was fully subscribed, with anchor investor allocation completed in January 2026. Additionally, the company completed a rights issue of 45,000 shares at ₹130 each in September 2025, raising ₹58.50 lacs for working capital requirements.

As of March 31, 2026, unutilized IPO proceeds of ₹655.48 lacs were parked in short-term fixed deposits, significantly strengthening the balance sheet. This influx of capital reduced the Debt-Equity ratio sharply from 0.76 in FY25 to 0.12 in FY26. Consequently, the Current Ratio improved dramatically to 11.98 from 2.87, providing ample liquidity for future expansion plans.

Operational Milestones

Accretion Nutraveda continues to leverage its WHO-GMP, AYUSH GMP, and ISO 9001:2015 certified manufacturing facility in Sanand, Gujarat. The company reported an installed capacity of 71.645 million units across tablets, capsules, oral liquids, and oils. Management highlighted that strategic investments in automated machinery are underway to enhance production efficiency and support margin expansion in subsequent quarters.

The workforce grew to 24 employees as of March 2026, up from 17 in the previous year, reflecting hiring in key technical and operational roles. The company maintains a B2B business model, serving both domestic clients and international export markets, with foreign exchange earnings totaling ₹11.04 lacs in FY26.

What the Numbers Show

The divergence between revenue growth (110%) and the slight compression in EBITDA margin (from 22.79% to 20.85%) suggests that Accretion Nutraveda is prioritizing market share expansion and capacity utilization over immediate margin maximization. However, the substantial improvement in liquidity metrics—driven by the IPO—positions the company to absorb higher working capital needs without relying on expensive debt. The sharp decline in Return on Net Worth (from 49.50% to 14.29%) is a mathematical consequence of the massive increase in equity base rather than operational underperformance, a typical pattern post-IPO that should normalize as deployed capital begins generating returns.

Accretion Nutraveda Limited has informed BSE Limited about an upcoming Board of Directors meeting scheduled for May 8, 2026. The meeting intimation was filed on May 1, 2026, in accordance with regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The board meeting has been convened primarily to consider and approve the company's audited financial results for the fiscal year that concluded on March 31, 2026. This represents a crucial milestone for stakeholders as it will provide comprehensive insights into the company's financial performance for FY26.

Company Information

Accretion Nutraveda Limited, formerly known as Accretion Nutraveda Private Limited, is listed on BSE Limited with scrip code 544694. The company secretary and compliance officer, Payal Kotadiya, signed the board meeting intimation digitally on May 1, 2026.

Regulatory Compliance

The intimation follows the mandatory disclosure requirements under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results are scheduled for consideration and approval.

The upcoming board meeting represents a standard corporate governance practice, ensuring transparency and timely disclosure of financial information to investors and regulatory authorities.